### Appendix 3B

# New issue announcement, application for quotation of additional securities and agreement

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 01/07/96 Origin: Appendix 5 Amended 01/07/98, 01/09/99, 01/07/00, 30/09/01, 11/03/02, 01/01/03, 24/10/05, 01/08/12, 04/03/13

Name of entity	
Catapult Group International Ltd	
ABN	
53 164 301 197	
We (the entity) give ASX the follow	ing information.

#### Part 1 - All issues

You must complete the relevant sections (attach sheets if there is not enough space).

†Class of †securities issued or to be issued

Unlisted options

Number of \*securities issued or to be issued (if known) or maximum number which may be issued 3,000,000 unlisted options

Principal terms of the \*securities (e.g. if options, exercise price and expiry date; if partly paid \*securities, the amount outstanding and due dates for payment; if \*convertible securities, the conversion price and dates for conversion)

2,000,000 unlisted and unvested options, which have the following terms:

- 500,000 unlisted options, each exercisable at \$2.54, which vest on 1 May 2018 subject to meeting performance hurdles set by the Board of Directors;
- 500,000 unlisted options, each exercisable at \$2.54, which vest on 1 May 2019 subject to meeting performance hurdles set by the Board of Directors;
- 500,000 unlisted options, each exercisable at \$2.54, which vest on 1 May 2020 subject to meeting performance

<sup>+</sup> See chapter 19 for defined terms.

hurdles set by the Board of Directors; and
 500,000 unlisted options, each exercisable at \$2.54, which vest on 1 May 2021 subject to meeting performance hurdles set by the Board of Directors.

750,000 unlisted and unvested options, which have the following terms:

- 150,000 unlisted options, each exercisable at \$3.88, which vest on 1 May 2018 subject to meeting performance hurdles set by the Board of Directors.
- 150,000 unlisted options, each exercisable at \$3.88, which vest on 1 May 2019 subject to meeting performance hurdles set by the Board of Directors.
- 150,000 unlisted options, each exercisable at \$3.88, which vest on 1 May 2020 subject to meeting performance hurdles set by the Board of Directors.
- 150,000 unlisted options, each exercisable at \$3.88, which vest on 1 May 2021 subject to meeting performance hurdles set by the Board of Directors.
- 150,000 unlisted options, each exercisable at \$3.88, which vest on 1 May 2022 subject to meeting performance hurdles set by the Board of Directors.

250,000 unlisted and unvested options, which have the following terms:

- 50,000 unlisted options, each exercisable at \$3.53, which vest on 1 May 2018 subject to meeting performance hurdles set by the Board of Directors.
- 50,000 unlisted options, each exercisable at \$3.53, which vest on 1 May 2019 subject to meeting performance hurdles set by the Board of Directors.
- 50,000 unlisted options, each exercisable at \$3.53, which vest on 1 May 2020 subject to meeting performance hurdles set by the Board of Directors.
- 50,000 unlisted options, each exercisable at \$3.53, which vest on 1 May 2021 subject to meeting performance hurdles set by the Board of Directors.
- 50,000 unlisted options, each exercisable at \$3.53, which vest on 1 May 2022 subject to meeting performance hurdles set by the Board of Directors.

Yes, upon exercise, the options will rank 4 Do the +securities rank equally in equally with the quoted fully paid ordinary all respects from the +issue date with an existing +class of quoted shares. +securities? If the additional \*securities do not rank equally, please state: the date from which they do the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment the extent to which they do not rank equally, other than in relation to the next dividend, distribution interest payment Issue price or consideration Nil. 5 Purpose of the issue Issue of unlisted options to employees under (If issued as consideration for the the terms and conditions of the Employee acquisition of assets, clearly Share Plan the terms of which were disclosed identify those assets) in the Company's IPO prospectus. 6a Is the entity an +eligible entity No that has obtained security holder approval under rule 7.1A? If Yes, complete sections 6b – 6h in relation to the +securities the subject of this Appendix 3B, and comply with section 6i 6b The date the security holder N/A resolution under rule 7.1A was passed

under rule 7.1

Number of \*securities issued without security holder approval

6c

04/03/2013 Appendix 3B Page 3

N/A

<sup>+</sup> See chapter 19 for defined terms.

6d	Number of *securities issued with security holder approval under rule 7.1A	N/A	
6e	Number of *securities issued with security holder approval under rule 7.3, or another specific security holder approval (specify date of meeting)	3,000,000 unlisted a (exception 9(a) of List	and unvested options ing Rule 7.2).
6f	Number of *securities issued under an exception in rule 7.2	N/A	
6g	If *securities issued under rule 7.1A, was issue price at least 75% of 15 day VWAP as calculated under rule 7.1A.3? Include the *issue date and both values. Include the source of the VWAP calculation.	N/A	
6h	If *securities were issued under rule 7.1A for non-cash consideration, state date on which valuation of consideration was released to ASX Market Announcements	N/A	
6i	Calculate the entity's remaining issue capacity under rule 7.1 and rule 7.1A – complete Annexure 1 and release to ASX Market Announcements	See Annexure 1	
_	+T J-1	- May a or	
7	*Issue dates  Note: The issue date may be prescribed by ASX (refer to the definition of issue date in rule 19.12). For example, the issue date for a pro rata entitlement issue must comply with the applicable timetable in Appendix 7A.  Cross reference: item 33 of Appendix 3B.	1 May 2017	
	33 11 3		
8	Number and *class of all *securities quoted on ASX (including the *securities in section 2 if applicable)	Number 158,184,617	+Class Fully paid ordinary shares
	Nui	mber	+Class

9	Number and *class of all *securities not quoted on ASX (including the *securities in section 2 if applicable)	1,664,400	1 option (over unissued fully paid ordinary shares) expiring on 6 June 2017.
		2,847,000	Treasury shares held by the Employee Share Plan trust.
		510,000	Unlisted and unvested performance rights, which expire on 30 November 2017.
		746,488*	Unlisted options, each exercisable at \$2.20 on or before 14 April 2021.
		50,000*	Unlisted options, each exercisable at \$2.31 on or before 1 January 2021.
		300,000*	Unlisted options, each exercisable at \$1.55 on or before 1 January 2021.
		90,000*	Unlisted options, each exercisable at \$1.68 on or before 14 April 2021.
		50,000*	Unlisted options, each exercisable at \$4.46.
		300,000*	Unlisted options, each exercisable at \$3.78.
		200,000*	Unlisted options, each exercisable at the 30 day VWAP on their respective dates of vesting.
		100,000*	Unlisted options, each exercisable at \$3.61.
		700,000*	Unlisted options, each exercisable at \$3.82.
		300,000*	Unlisted options, each exercisable at \$3.82.
		450,000*	Unlisted options, each exercisable at the 30 day VWAP on 30 June 2017.
		105,000	Performance rights, each with a zero exercise price.

<sup>+</sup> See chapter 19 for defined terms.

100,000	Unlisted and unvested performance rights, each with a nil exercise price, which vest on 22 March 2017 and expire 22 September 2017.
100,000	Unlisted and unvested performance rights, each with a nil exercise price, which vest on 22 March 2018 and expire 22 September 2018.
100,000	Unlisted and unvested performance rights, each with a nil exercise price, which vest on 22 March 2019 and expire 22 September 2019.
500,000	Unlisted and unvested options, each exercisable at \$4.284, which vest on 22 September 2017 and expire 24 March 2018;
500,000	Unlisted and unvested options, each exercisable at \$4.843, which vest on 22 September 2018 and expire 24 March 2019;
500,000	Unlisted and unvested options, each exercisable at \$4.843, which vest on 22 September 2019 and expire 23 March 2020;
500,000	Unlisted options, each exercisable at \$2.54, which vest on 1 May 2018;
500,000	Unlisted options, each exercisable at \$2.54, which vest on 1 May 2019;
500,000	Unlisted options, each exercisable at \$2.54, which vest on 1 May 2020;
500,000	Unlisted options, each exercisable at \$2.54, which vest on 1 May 2021;
150,000	Unlisted options, each exercisable at \$3.88, which vest on 1 May 2018;

	150,000	Unlisted options, each exercisable at \$3.88, which vest on 1 May 2019;
	150,000	Unlisted options, each exercisable at \$3.88, which vest on 1 May 2020;
	150,000	Unlisted options, each exercisable at \$3.88, which vest on 1 May 2021;
	150,000	Unlisted options, each exercisable at \$3.88, which vest on 1 May 2022;
	50,000	Unlisted options, each exercisable at \$3.53, which vest on 1 May 2018;
	50,000	Unlisted options, each exercisable at \$3.53, which vest on 1 May 2019;
	50,000	Unlisted options, each exercisable at \$3.53, which vest on 1 May 2020;
	50,000	Unlisted options, each exercisable at \$3.53, which vest on 1 May 2021;
	50,000	Unlisted options, each exercisable at \$3.53, which vest on 1 May 2022.
	*Note: 569,000 of these option will not convert to new shares, the Employee Share Plan trust the exercise of these options dilutionary effect on the issued	but be issued shares from (see above). Accordingly, will have no additional
Dividend policy (in the case of a trust, distribution policy) on the increased capital (interests)	N/A	

policy) on the increased capital (interests)

#### Part 2 - Pro rata issue

10

holder appro	rova	ıl	1	ıl
--------------	------	----	---	----

<sup>+</sup> See chapter 19 for defined terms.

12	Is the issue renounceable or non-renounceable?
13	Ratio in which the *securities will be offered
14	<sup>+</sup> Class of <sup>+</sup> securities to which the offer relates
15	<sup>+</sup> Record date to determine entitlements
16	Will holdings on different registers (or subregisters) be aggregated for calculating entitlements?
17	Policy for deciding entitlements in relation to fractions
18	Names of countries in which the entity has security holders who will not be sent new offer documents
	Note: Security holders must be told how their entitlements are to be dealt with.
	Cross reference: rule 7.7.
19	Closing date for receipt of acceptances or renunciations

20	Names of any underwriters	
21	Amount of any underwriting fee or commission	
22	Names of any brokers to the issue	
23	Fee or commission payable to the broker to the issue	
24	Amount of any handling fee payable to brokers who lodge acceptances or renunciations on behalf of security holders	
25	If the issue is contingent on security holders' approval, the date of the meeting	
26	Date entitlement and acceptance form and offer documents will be sent to persons entitled	
27	If the entity has issued options, and the terms entitle option holders to participate on exercise, the date on which notices will be sent to option holders	
28	Date rights trading will begin (if applicable)	
29	Date rights trading will end (if applicable)	
30	How do security holders sell their entitlements <i>in full</i> through a broker?	
31	How do security holders sell <i>part</i> of their entitlements through a broker and accept for the balance?	

<sup>+</sup> See chapter 19 for defined terms.

32	of the	do security holders dispose ir entitlements (except by brough a broker)?
33	<sup>+</sup> Issue	date
		Otation of securities  mplete this section if you are applying for quotation of securities
34	Type of (tick o	of <sup>+</sup> securities ne)
(a)		+Securities described in Part 1
(b)		All other <sup>+</sup> securities  Example: restricted securities at the end of the escrowed period, partly paid securities that become fully paid employee incentive share securities when restriction ends, securities issued on expiry or conversion of convertible securities
Entities	s that I	nave ticked box 34(a)
Additi	onal s	ecurities forming a new class of securities
Tick to docume		you are providing the information or
35		If the *securities are *equity securities, the names of the 20 largest holders of the additional *securities, and the number and percentage of additional *securities held by those holders
36		If the *securities are *equity securities, a distribution schedule of the additiona *securities setting out the number of holders in the categories 1 - 1,000 1,001 - 5,000 5,001 - 10,000 10,001 - 100,000 100,001 and over
37		A copy of any trust deed for the additional *securities

Appendix 3B Page 10 04/03/2013

<sup>+</sup> See chapter 19 for defined terms.

Entities	s that have ticked box 34(b)		
38	Number of *securities for which *quotation is sought		
39	<sup>+</sup> Class of <sup>+</sup> securities for which quotation is sought		
40	Do the *securities rank equally in all respects from the *issue date with an existing *class of quoted *securities?		
	If the additional *securities do not rank equally, please state:  • the date from which they do  • the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment  • the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment		
41	Reason for request for quotation now  Example: In the case of restricted securities, end of restriction period		
	(if issued upon conversion of another *security, clearly identify that other *security)		
		N1	+Cl
42	Number and +class of all	Number	<sup>+</sup> Class
•	*securities quoted on ASX ( <i>including</i> the *securities in clause		

38)

<sup>+</sup> See chapter 19 for defined terms.

#### **Quotation agreement**

- <sup>†</sup>Quotation of our additional <sup>†</sup>securities is in ASX's absolute discretion. ASX may quote the <sup>†</sup>securities on any conditions it decides.
- 2 We warrant the following to ASX.
  - The issue of the \*securities to be quoted complies with the law and is not for an illegal purpose.
  - There is no reason why those \*securities should not be granted \*quotation.
  - An offer of the \*securities for sale within 12 months after their issue will not require disclosure under section 707(3) or section 1012C(6) of the Corporations Act.

Note: An entity may need to obtain appropriate warranties from subscribers for the securities in order to be able to give this warranty

- Section 724 or section 1016E of the Corporations Act does not apply to any applications received by us in relation to any \*securities to be quoted and that no-one has any right to return any \*securities to be quoted under sections 737, 738 or 1016F of the Corporations Act at the time that we request that the \*securities be quoted.
- If we are a trust, we warrant that no person has the right to return the \*securities to be quoted under section 1019B of the Corporations Act at the time that we request that the \*securities be quoted.
- We will indemnify ASX to the fullest extent permitted by law in respect of any claim, action or expense arising from or connected with any breach of the warranties in this agreement.
- We give ASX the information and documents required by this form. If any information or document is not available now, we will give it to ASX before †quotation of the †securities begins. We acknowledge that ASX is relying on the information and documents. We warrant that they are (will be) true and complete.

Sign here: Date: 1 May 2017

Company secretary

Print name: Anand Sundaraj

Appendix 3B Page 12 04/03/2013

<sup>+</sup> See chapter 19 for defined terms.

## Appendix 3B – Annexure 1

## Calculation of placement capacity under rule 7.1 and rule 7.1A for eligible entities

Introduced 01/08/12 Amended 04/03/13

#### Part 1

Rule 7.1 – Issues exceeding 15% of capital		
Step 1: Calculate "A", the base fig capacity is calculated	ure from which the placement	
Insert number of fully paid +ordinary securities on issue 12 months before the +issue date or date of agreement to issue	124,425,588	
Add the following:	8,569,259 (issued on 25 July 2016)	
<ul> <li>Number of fully paid +ordinary securities issued in that 12 month period under an exception in rule 7.2</li> <li>Number of fully paid +ordinary securities issued in that 12 month period with shareholder approval</li> <li>Number of partly paid +ordinary securities that became fully paid in that 12 month period</li> <li>Note:         <ul> <li>Include only ordinary securities here – other classes of equity securities cannot be added</li> <li>Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed</li> <li>It may be useful to set out issues of securities on different dates as separate line items</li> </ul> </li> </ul>	21,912,014 (issued on 25 July 2016, ratified on 30 November 2016)  2,853,177 (issued on 11 August 2016)  424,579 (issued on 12 August 2016, ratified on 30 November 2016)	
Subtract the number of fully paid  +ordinary securities cancelled during that 12 month period	Nil	
"A"	158,184,617	

<sup>+</sup> See chapter 19 for defined terms.

Step 2: Calculate 15% of "A"	
"B"	0.15
	[Note: this value cannot be changed]
Multiply "A" by 0.15	23,727,692 (rounded up)
Step 3: Calculate "C", the amount 7.1 that has already been used	of placement capacity under rule
Insert number of *equity securities issued or agreed to be issued in that 12 month period not counting those issued:	Nil
Under an exception in rule 7.2	
Under rule 7.1A	
With security holder approval under rule 7.1 or rule 7.4	
<ul> <li>Note:</li> <li>This applies to equity securities, unless specifically excluded – not just ordinary securities</li> <li>Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed</li> <li>It may be useful to set out issues of securities on different dates as separate line items</li> </ul>	
"C"	Nil
Step 4: Subtract "C" from ["A" x " placement capacity under rule 7.1	B"] to calculate remaining
"A" x 0.15	23,727,692
Note: number must be same as shown in Step 2	
Subtract "C"	Nil
Note: number must be same as shown in Step 3	
<b>Total</b> ["A" x 0.15] – "C"	23,727,692
	[Note: this is the remaining placement capacity under rule 7.1]

Appendix 3B Page 14 04/03/2013

<sup>+</sup> See chapter 19 for defined terms.

Rule 7.1A – Additional placement capacity for eligible entities  Step 1: Calculate "A", the base figure from which the placement capacity is calculated	
Note: number must be same as shown in Step 1 of Part 1	
Step 2: Calculate 10% of "A"	
"D"	0.10
	Note: this value cannot be changed
Multiply "A" by 0.10	15,818,461 (rounded up)
Step 3: Calculate "E", the amount of placement capacity under rule 7.1A that has already been used	
Insert number of *equity securities issued or agreed to be issued in that 12-month period under rule 7.1A  Notes:  This applies to equity securities – not just ordinary securities  Include here – if applicable – the securities the subject of the Appendix 3B to which this form is annexed  Do not include equity securities issued under rule 7.1 (they must be dealt with in Part 1), or for which specific security holder approval has been obtained  It may be useful to set out issues of securities on different dates as	Nil
"E"	Nil

<sup>+</sup> See chapter 19 for defined terms.

Step 4: Subtract "E" from ["A" x "D"] to calculate remaining placement capacity under rule 7.1A	
"A" x 0.10	15,818,461
Note: number must be same as shown in Step 2	
Subtract "E"	0
Note: number must be same as shown in Step 3	
<b>Total</b> ["A" x 0.10] – "E"	15,818,461
	Note: this is the remaining placement capacity under rule 7.1A

Appendix 3B Page 16 04/03/2013

<sup>+</sup> See chapter 19 for defined terms.